Surabgene Lomparvovec (ABBV-RGX-314), Lucentis 10 mg/ml solution for injection in pre-filled syringe, Surabgene Lomparvovec (ABBV-RGX-314)
M24-528
Approved small_molecule active
Quick answer
Surabgene Lomparvovec (ABBV-RGX-314), Lucentis 10 mg/ml solution for injection in pre-filled syringe, Surabgene Lomparvovec (ABBV-RGX-314) for Neovascular age-related macular degeneration is a Approved program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Neovascular age-related macular degeneration
- Phase
- Approved
- Modality
- small_molecule
- Status
- active